APO Research

APO RESEARCH · REPORT

T Cell Antigen Gp39

Selected research

Industry Growth & Trends

Global T Cell Antigen Gp39 Industry Growth and Trends Forecast to 2032

Market perspective

The global T Cell Antigen Gp39 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of T Cell Antigen Gp39 include Biogen, Inc., XL-protein GmbH, Targovax AS, MedImmune, LLC, Juno Therapeutics Inc., ImmuNext, Inc., eTheRNA Immunotherapies NV and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global T Cell Antigen Gp39 market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The T Cell Antigen Gp39 market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global T Cell Antigen Gp39 market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to T Cell Antigen Gp39.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global T Cell Antigen Gp39 market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

T Cell Antigen Gp39 Market by Company

Biogen, Inc.

XL-protein GmbH

Targovax AS

MedImmune, LLC

Juno Therapeutics Inc.

ImmuNext, Inc.

eTheRNA Immunotherapies NV

Bristol-Myers Squibb Company

T Cell Antigen Gp39 Segment by Type

ECI-006

Hepatitis B Vaccine

ISF-35

INX-021

Others

T Cell Antigen Gp39 Segment by Application

Graft Versus Host Disease

Panceratic Cancer

Breast Cancer

Bladder Cancer

Others

T Cell Antigen Gp39 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Antigen Gp39 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T Cell Antigen Gp39 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Antigen Gp39.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of T Cell Antigen Gp39 manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of T Cell Antigen Gp39 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of ECI-006 Table 2. Major Company of Hepatitis B Vaccine Table 3. Major Company of ISF-35 Table 4. Major Company of INX-021 Table 5. Major Company of Others Table 6. Global T Cell Antigen Gp39 Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global T Cell Antigen Gp39 Sales by Type (2021-2026) & (K Units) Table 8. Global T Cell Antigen Gp39 Sales Market Share in Volume by Type (2021-2026) Table 9. Global T Cell Antigen Gp39 Sales by Type (2021-2026) & (US$ Million) Table 10. Global T Cell Antigen Gp39 Sales Market Share in Value by Type (2021-2026) Table 11. Global T Cell Antigen Gp39 Price by Type (2021-2026) & (US$/Unit) Table 12. Global T Cell Antigen Gp39 Sales by Type (2027-2032) & (K Units) Table 13. Global T Cell Antigen Gp39 Sales Market Share in Volume by Type (2027-2032) Table 14. Global T Cell Antigen Gp39 Sales by Type (2027-2032) & (US$ Million) Table 15. Global T Cell Antigen Gp39 Sales Market Share in Value by Type (2027-2032) Table 16. Global T Cell Antigen Gp39 Price by Type (2027-2032) & (US$/Unit) Table 17. North America T Cell Antigen Gp39 Sales by Type (2021-2026) & (K Units) Table 18. North America T Cell Antigen Gp39 Sales by Type (2021-2026) & (US$ Million) Table 19. Europe T Cell Antigen Gp39 Sales by Type (2021-2026) & (K Units) Table 20. Europe T Cell Antigen Gp39 Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific T Cell Antigen Gp39 Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific T Cell Antigen Gp39 Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America T Cell Antigen Gp39 Sales by Type (2021-2026) & (K Units) Table 24. Latin America T Cell Antigen Gp39 Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa T Cell Antigen Gp39 Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa T Cell Antigen Gp39 Sales by Type (2021-2026) & (US$ Million) Table 27. T Cell Antigen Gp39 Industry Trends Table 28. T Cell Antigen Gp39 Industry Drivers Table 29. T Cell Antigen Gp39 Industry Opportunities and Challenges Table 30. T Cell Antigen Gp39 Industry Restraints Table 31. Global T Cell Antigen Gp39 Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global T Cell Antigen Gp39 Revenue Market Share by Company (2021-2026) Table 33. Global T Cell Antigen Gp39 Sales by Company (2021-2026) & (K Units) Table 34. Global T Cell Antigen Gp39 Sales Share by Company (2021-2026) Table 35. Global T Cell Antigen Gp39 Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global T Cell Antigen Gp39 Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global T Cell Antigen Gp39 Major Company Production Sites and Headquarters Table 38. Global T Cell Antigen Gp39 Company, Product Type & Application Table 39. Global T Cell Antigen Gp39 Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global T Cell Antigen Gp39 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global T Cell Antigen Gp39 Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global T Cell Antigen Gp39 Sales by Region (2021-2026) & (K Units) Table 44. Global T Cell Antigen Gp39 Sales Market Share in Volume by Region (2021-2026) Table 45. Global T Cell Antigen Gp39 Sales by Region (2021-2026) & (US$ Million) Table 46. Global T Cell Antigen Gp39 Sales Market Share in Value by Region (2021-2026) Table 47. Global T Cell Antigen Gp39 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global T Cell Antigen Gp39 Sales by Region (2027-2032) & (K Units) Table 49. Global T Cell Antigen Gp39 Sales Market Share in Volume by Region (2027-2032) Table 50. Global T Cell Antigen Gp39 Sales by Region (2027-2032) & (US$ Million) Table 51. Global T Cell Antigen Gp39 Sales Market Share in Value by Region (2027-2032) Table 52. Global T Cell Antigen Gp39 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global T Cell Antigen Gp39 Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global T Cell Antigen Gp39 Sales by Application (2021-2026) & (K Units) Table 55. Global T Cell Antigen Gp39 Sales Market Share in Volume by Application (2021-2026) Table 56. Global T Cell Antigen Gp39 Sales by Application (2021-2026) & (US$ Million) Table 57. Global T Cell Antigen Gp39 Sales Market Share in Value by Application (2021-2026) Table 58. Global T Cell Antigen Gp39 Price by Application (2021-2026) & (US$/Unit) Table 59. Global T Cell Antigen Gp39 Sales by Application (2027-2032) & (K Units) Table 60. Global T Cell Antigen Gp39 Sales Market Share in Volume by Application (2027-2032) Table 61. Global T Cell Antigen Gp39 Sales by Application (2027-2032) & (US$ Million) Table 62. Global T Cell Antigen Gp39 Sales Market Share in Value by Application (2027-2032) Table 63. Global T Cell Antigen Gp39 Price by Application (2027-2032) & (US$/Unit) Table 64. North America T Cell Antigen Gp39 Sales by Application (2021-2026) & (K Units) Table 65. North America T Cell Antigen Gp39 Sales by Application (2021-2026) & (US$ Million) Table 66. Europe T Cell Antigen Gp39 Sales by Application (2021-2026) & (K Units) Table 67. Europe T Cell Antigen Gp39 Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific T Cell Antigen Gp39 Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific T Cell Antigen Gp39 Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America T Cell Antigen Gp39 Sales by Application (2021-2026) & (K Units) Table 71. Latin America T Cell Antigen Gp39 Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa T Cell Antigen Gp39 Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa T Cell Antigen Gp39 Sales by Application (2021-2026) & (US$ Million) Table 74. Biogen, Inc. Company Information Table 75. Biogen, Inc. Business Overview Table 76. Biogen, Inc. T Cell Antigen Gp39 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Biogen, Inc. T Cell Antigen Gp39 Product Portfolio Table 78. Biogen, Inc. Recent Development Table 79. XL-protein GmbH Company Information Table 80. XL-protein GmbH Business Overview Table 81. XL-protein GmbH T Cell Antigen Gp39 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. XL-protein GmbH T Cell Antigen Gp39 Product Portfolio Table 83. XL-protein GmbH Recent Development Table 84. Targovax AS Company Information Table 85. Targovax AS Business Overview Table 86. Targovax AS T Cell Antigen Gp39 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Targovax AS T Cell Antigen Gp39 Product Portfolio Table 88. Targovax AS Recent Development Table 89. MedImmune, LLC Company Information Table 90. MedImmune, LLC Business Overview Table 91. MedImmune, LLC T Cell Antigen Gp39 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. MedImmune, LLC T Cell Antigen Gp39 Product Portfolio Table 93. MedImmune, LLC Recent Development Table 94. Juno Therapeutics Inc. Company Information Table 95. Juno Therapeutics Inc. Business Overview Table 96. Juno Therapeutics Inc. T Cell Antigen Gp39 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio Table 98. Juno Therapeutics Inc. Recent Development Table 99. ImmuNext, Inc. Company Information Table 100. ImmuNext, Inc. Business Overview Table 101. ImmuNext, Inc. T Cell Antigen Gp39 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio Table 103. ImmuNext, Inc. Recent Development Table 104. eTheRNA Immunotherapies NV Company Information Table 105. eTheRNA Immunotherapies NV Business Overview Table 106. eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio Table 108. eTheRNA Immunotherapies NV Recent Development Table 109. Bristol-Myers Squibb Company Company Information Table 110. Bristol-Myers Squibb Company Business Overview Table 111. Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio Table 113. Bristol-Myers Squibb Company Recent Development Table 114. North America T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 115. North America T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units) Table 116. North America T Cell Antigen Gp39 Sales Market Share by Country (2021-2026) Table 117. North America T Cell Antigen Gp39 Sales Forecast by Country (2027-2032) & (K Units) Table 118. North America T Cell Antigen Gp39 Sales Market Share Forecast by Country (2027-2032) Table 119. North America T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 120. North America T Cell Antigen Gp39 Market Size by Country (2021-2026) & (US$ Million) Table 121. North America T Cell Antigen Gp39 Market Share by Country (2021-2026) Table 122. North America T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 123. North America T Cell Antigen Gp39 Market Share Forecast by Country (2027-2032) Table 124. Europe T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 125. Europe T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units) Table 126. Europe T Cell Antigen Gp39 Sales Market Share by Country (2021-2026) Table 127. Europe T Cell Antigen Gp39 Sales Forecast by Country (2027-2032) & (K Units) Table 128. Europe T Cell Antigen Gp39 Sales Market Share Forecast by Country (2027-2032) Table 129. Europe T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 130. Europe T Cell Antigen Gp39 Market Size by Country (2021-2026) & (US$ Million) Table 131. Europe T Cell Antigen Gp39 Market Share by Country (2021-2026) Table 132. Europe T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 133. Europe T Cell Antigen Gp39 Market Share Forecast by Country (2027-2032) Table 134. Asia-Pacific T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 135. Asia-Pacific T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units) Table 136. Asia-Pacific T Cell Antigen Gp39 Sales Market Share by Country (2021-2026) Table 137. Asia-Pacific T Cell Antigen Gp39 Sales Forecast by Country (2027-2032) & (K Units) Table 138. Asia-Pacific T Cell Antigen Gp39 Sales Market Share Forecast by Country (2027-2032) Table 139. Asia-Pacific T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. Asia-Pacific T Cell Antigen Gp39 Market Size by Country (2021-2026) & (US$ Million) Table 141. Asia-Pacific T Cell Antigen Gp39 Market Share by Country (2021-2026) Table 142. Asia-Pacific T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. Asia-Pacific T Cell Antigen Gp39 Market Share Forecast by Country (2027-2032) Table 144. Latin America T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 145. Latin America T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units) Table 146. Latin America T Cell Antigen Gp39 Sales Market Share by Country (2021-2026) Table 147. Latin America T Cell Antigen Gp39 Sales Forecast by Country (2027-2032) & (K Units) Table 148. Latin America T Cell Antigen Gp39 Sales Market Share Forecast by Country (2027-2032) Table 149. Latin America T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Latin America T Cell Antigen Gp39 Market Size by Country (2021-2026) & (US$ Million) Table 151. Latin America T Cell Antigen Gp39 Market Share by Country (2021-2026) Table 152. Latin America T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Latin America T Cell Antigen Gp39 Market Share Forecast by Country (2027-2032) Table 154. Middle East and Africa T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 155. Middle East and Africa T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units) Table 156. Middle East and Africa T Cell Antigen Gp39 Sales Market Share by Country (2021-2026) Table 157. Middle East and Africa T Cell Antigen Gp39 Sales Forecast by Country (2027-2032) & (K Units) Table 158. Middle East and Africa T Cell Antigen Gp39 Sales Market Share Forecast by Country (2027-2032) Table 159. Middle East and Africa T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Middle East and Africa T Cell Antigen Gp39 Market Size by Country (2021-2026) & (US$ Million) Table 161. Middle East and Africa T Cell Antigen Gp39 Market Share by Country (2021-2026) Table 162. Middle East and Africa T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Middle East and Africa T Cell Antigen Gp39 Market Share Forecast by Country (2027-2032) Table 164. Key Raw Materials Table 165. Raw Materials Key Suppliers Table 166. T Cell Antigen Gp39 Distributors List Table 167. T Cell Antigen Gp39 Customers List Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. T Cell Antigen Gp39 Image Figure 2. Global T Cell Antigen Gp39 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global T Cell Antigen Gp39 Market Size (2021-2032) & (US$ Million) Figure 4. Global T Cell Antigen Gp39 Sales (2021-2032) & (K Units) Figure 5. ECI-006 Image Figure 6. Global ECI-006 Sales YoY Growth (2021-2032) & (K Units) Figure 7. Hepatitis B Vaccine Image Figure 8. Global Hepatitis B Vaccine Sales YoY Growth (2021-2032) & (K Units) Figure 9. ISF-35 Image Figure 10. Global ISF-35 Sales YoY Growth (2021-2032) & (K Units) Figure 11. INX-021 Image Figure 12. Global INX-021 Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global T Cell Antigen Gp39 Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global T Cell Antigen Gp39 Market Share by Type 2025 VS 2032 Figure 17. North America T Cell Antigen Gp39 Sales Market Share in Volume by Type in 2025 Figure 18. North America T Cell Antigen Gp39 Sales Market Share in Value by Type in 2025 Figure 19. Europe T Cell Antigen Gp39 Sales Market Share in Volume by Type in 2025 Figure 20. Europe T Cell Antigen Gp39 Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific T Cell Antigen Gp39 Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific T Cell Antigen Gp39 Sales Market Share in Value by Type in 2025 Figure 23. Latin America T Cell Antigen Gp39 Sales Market Share in Volume by Type in 2025 Figure 24. Latin America T Cell Antigen Gp39 Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa T Cell Antigen Gp39 Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa T Cell Antigen Gp39 Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 T Cell Antigen Gp39 Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Graft Versus Host Disease Image Figure 30. Global Graft Versus Host Disease Sales YoY Growth (2021-2032) & (K Units) Figure 31. Panceratic Cancer Image Figure 32. Global Panceratic Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 33. Breast Cancer Image Figure 34. Global Breast Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 35. Bladder Cancer Image Figure 36. Global Bladder Cancer Sales YoY Growth (2021-2032) & (K Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 39. Global T Cell Antigen Gp39 Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global T Cell Antigen Gp39 Market Share by Application 2025 VS 2032 Figure 41. North America T Cell Antigen Gp39 Sales Market Share in Volume by Application in 2025 Figure 42. North America T Cell Antigen Gp39 Sales Market Share in Value by Application in 2025 Figure 43. Europe T Cell Antigen Gp39 Sales Market Share in Volume by Application in 2025 Figure 44. Europe T Cell Antigen Gp39 Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific T Cell Antigen Gp39 Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific T Cell Antigen Gp39 Sales Market Share in Value by Application in 2025 Figure 47. Latin America T Cell Antigen Gp39 Sales Market Share in Volume by Application in 2025 Figure 48. Latin America T Cell Antigen Gp39 Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa T Cell Antigen Gp39 Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa T Cell Antigen Gp39 Sales Market Share in Value by Application in 2025 Figure 51. North America T Cell Antigen Gp39 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. North America T Cell Antigen Gp39 Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America T Cell Antigen Gp39 Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe T Cell Antigen Gp39 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Europe T Cell Antigen Gp39 Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe T Cell Antigen Gp39 Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific T Cell Antigen Gp39 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Asia-Pacific T Cell Antigen Gp39 Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific T Cell Antigen Gp39 Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America T Cell Antigen Gp39 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Latin America T Cell Antigen Gp39 Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America T Cell Antigen Gp39 Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa T Cell Antigen Gp39 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Middle East and Africa T Cell Antigen Gp39 Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa T Cell Antigen Gp39 Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa T Cell Antigen Gp39 Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. T Cell Antigen Gp39 Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. T Cell Antigen Gp39 Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • ECI-006
  • Hepatitis B Vaccine
  • ISF-35
  • INX-021
  • Others
Applications
  • Graft Versus Host Disease
  • Panceratic Cancer
  • Breast Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Biogen, Inc.
  • XL-protein GmbH
  • Targovax AS
  • MedImmune, LLC
  • Juno Therapeutics Inc.
  • ImmuNext, Inc.
  • eTheRNA Immunotherapies NV
  • Bristol-Myers Squibb Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global T Cell Antigen Gp39 Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global T Cell Antigen Gp39 Sales Estimates and Forecasts (2021-2032)
  5. 1.3 T Cell Antigen Gp39 Market by Type
  6. 1.3.1 ECI-006
  7. 1.3.2 Hepatitis B Vaccine
  8. 1.3.3 ISF-35
  9. 1.3.4 INX-021
  10. 1.3.5 Others
  11. 1.4 Global T Cell Antigen Gp39 Market Size by Type
  12. 1.4.1 Global T Cell Antigen Gp39 Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global T Cell Antigen Gp39 Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global T Cell Antigen Gp39 Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America T Cell Antigen Gp39 Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe T Cell Antigen Gp39 Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific T Cell Antigen Gp39 Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America T Cell Antigen Gp39 Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa T Cell Antigen Gp39 Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 T Cell Antigen Gp39 Industry Trends
  2. 2.2 T Cell Antigen Gp39 Industry Drivers
  3. 2.3 T Cell Antigen Gp39 Industry Opportunities and Challenges
  4. 2.4 T Cell Antigen Gp39 Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by T Cell Antigen Gp39 Revenue (2021-2026)
  2. 3.2 Global Top Players by T Cell Antigen Gp39 Sales (2021-2026)
  3. 3.3 Global Top Players by T Cell Antigen Gp39 Price (2021-2026)
  4. 3.4 Global T Cell Antigen Gp39 Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global T Cell Antigen Gp39 Major Company Production Sites & Headquarters
  6. 3.6 Global T Cell Antigen Gp39 Company, Product Type & Application
  7. 3.7 Global T Cell Antigen Gp39 Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global T Cell Antigen Gp39 Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 T Cell Antigen Gp39 Players Market Share by Revenue in 2025
  11. 3.8.3 2025 T Cell Antigen Gp39 Tier 1, Tier 2, and Tier 3
4 T Cell Antigen Gp39 Regional Status and Outlook
  1. 4.1 Global T Cell Antigen Gp39 Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global T Cell Antigen Gp39 Historic Market Size by Region
  3. 4.2.1 Global T Cell Antigen Gp39 Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global T Cell Antigen Gp39 Sales in Value by Region (2021-2026)
  5. 4.2.3 Global T Cell Antigen Gp39 Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global T Cell Antigen Gp39 Forecasted Market Size by Region
  7. 4.3.1 Global T Cell Antigen Gp39 Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global T Cell Antigen Gp39 Sales in Value by Region (2027-2032)
  9. 4.3.3 Global T Cell Antigen Gp39 Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 T Cell Antigen Gp39 by Application
  1. 5.1 T Cell Antigen Gp39 Market by Application
  2. 5.1.1 Graft Versus Host Disease
  3. 5.1.2 Panceratic Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Bladder Cancer
  6. 5.1.5 Others
  7. 5.2 Global T Cell Antigen Gp39 Market Size by Application
  8. 5.2.1 Global T Cell Antigen Gp39 Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global T Cell Antigen Gp39 Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global T Cell Antigen Gp39 Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America T Cell Antigen Gp39 Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe T Cell Antigen Gp39 Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific T Cell Antigen Gp39 Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America T Cell Antigen Gp39 Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa T Cell Antigen Gp39 Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Biogen, Inc.
  2. 6.1.1 Biogen, Inc. Company Information
  3. 6.1.2 Biogen, Inc. Business Overview
  4. 6.1.3 Biogen, Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Biogen, Inc. T Cell Antigen Gp39 Product Portfolio
  6. 6.1.5 Biogen, Inc. Recent Developments
  7. 6.2 XL-protein GmbH
  8. 6.2.1 XL-protein GmbH Company Information
  9. 6.2.2 XL-protein GmbH Business Overview
  10. 6.2.3 XL-protein GmbH T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 XL-protein GmbH T Cell Antigen Gp39 Product Portfolio
  12. 6.2.5 XL-protein GmbH Recent Developments
  13. 6.3 Targovax AS
  14. 6.3.1 Targovax AS Company Information
  15. 6.3.2 Targovax AS Business Overview
  16. 6.3.3 Targovax AS T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Targovax AS T Cell Antigen Gp39 Product Portfolio
  18. 6.3.5 Targovax AS Recent Developments
  19. 6.4 MedImmune, LLC
  20. 6.4.1 MedImmune, LLC Company Information
  21. 6.4.2 MedImmune, LLC Business Overview
  22. 6.4.3 MedImmune, LLC T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 MedImmune, LLC T Cell Antigen Gp39 Product Portfolio
  24. 6.4.5 MedImmune, LLC Recent Developments
  25. 6.5 Juno Therapeutics Inc.
  26. 6.5.1 Juno Therapeutics Inc. Company Information
  27. 6.5.2 Juno Therapeutics Inc. Business Overview
  28. 6.5.3 Juno Therapeutics Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio
  30. 6.5.5 Juno Therapeutics Inc. Recent Developments
  31. 6.6 ImmuNext, Inc.
  32. 6.6.1 ImmuNext, Inc. Company Information
  33. 6.6.2 ImmuNext, Inc. Business Overview
  34. 6.6.3 ImmuNext, Inc. T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio
  36. 6.6.5 ImmuNext, Inc. Recent Developments
  37. 6.7 eTheRNA Immunotherapies NV
  38. 6.7.1 eTheRNA Immunotherapies NV Company Information
  39. 6.7.2 eTheRNA Immunotherapies NV Business Overview
  40. 6.7.3 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio
  42. 6.7.5 eTheRNA Immunotherapies NV Recent Developments
  43. 6.8 Bristol-Myers Squibb Company
  44. 6.8.1 Bristol-Myers Squibb Company Company Information
  45. 6.8.2 Bristol-Myers Squibb Company Business Overview
  46. 6.8.3 Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio
  48. 6.8.5 Bristol-Myers Squibb Company Recent Developments
7 North America by Country
  1. 7.1 North America T Cell Antigen Gp39 Sales by Country
  2. 7.1.1 North America T Cell Antigen Gp39 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America T Cell Antigen Gp39 Sales by Country (2021-2026)
  4. 7.1.3 North America T Cell Antigen Gp39 Sales Forecast by Country (2027-2032)
  5. 7.2 North America T Cell Antigen Gp39 Market Size by Country
  6. 7.2.1 North America T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America T Cell Antigen Gp39 Market Size by Country (2021-2026)
  8. 7.2.3 North America T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe T Cell Antigen Gp39 Sales by Country
  2. 8.1.1 Europe T Cell Antigen Gp39 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe T Cell Antigen Gp39 Sales by Country (2021-2026)
  4. 8.1.3 Europe T Cell Antigen Gp39 Sales Forecast by Country (2027-2032)
  5. 8.2 Europe T Cell Antigen Gp39 Market Size by Country
  6. 8.2.1 Europe T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe T Cell Antigen Gp39 Market Size by Country (2021-2026)
  8. 8.2.3 Europe T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific T Cell Antigen Gp39 Sales by Country
  2. 9.1.1 Asia-Pacific T Cell Antigen Gp39 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific T Cell Antigen Gp39 Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific T Cell Antigen Gp39 Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific T Cell Antigen Gp39 Market Size by Country
  6. 9.2.1 Asia-Pacific T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific T Cell Antigen Gp39 Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America T Cell Antigen Gp39 Sales by Country
  2. 10.1.1 South America T Cell Antigen Gp39 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America T Cell Antigen Gp39 Sales by Country (2021-2026)
  4. 10.1.3 South America T Cell Antigen Gp39 Sales Forecast by Country (2027-2032)
  5. 10.2 South America T Cell Antigen Gp39 Market Size by Country
  6. 10.2.1 South America T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America T Cell Antigen Gp39 Market Size by Country (2021-2026)
  8. 10.2.3 South America T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa T Cell Antigen Gp39 Sales by Country
  2. 11.1.1 Middle East and Africa T Cell Antigen Gp39 Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa T Cell Antigen Gp39 Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa T Cell Antigen Gp39 Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa T Cell Antigen Gp39 Market Size by Country
  6. 11.2.1 Middle East and Africa T Cell Antigen Gp39 Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa T Cell Antigen Gp39 Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa T Cell Antigen Gp39 Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 T Cell Antigen Gp39 Value Chain Analysis
  2. 12.1.1 T Cell Antigen Gp39 Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 T Cell Antigen Gp39 Production Mode & Process
  7. 12.2 T Cell Antigen Gp39 Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 T Cell Antigen Gp39 Distributors
  10. 12.2.3 T Cell Antigen Gp39 Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research